From humble beginnings to global reach, Galenika’s remarkable growth under Brazilian ownership demonstrates the power of strategic investments, innovation, and global partnerships.
Since becoming part of Brazil’s NC Group seven years ago, Serbia’s pharmaceutical giant, Galenika, has seen transformative growth.
The company has not only expanded its product portfolio but has also increased sales by a remarkable 84% in Serbia.
This year alone, Galenika reported an 11% rise in domestic sales and a 15% boost in regional markets.
With over 820 employees, the company now produces 330 products, including 30 that have been staples for more than 50 years.
Its strategic moves, such as building new factories and forming partnerships with global players like Spain’s Cantabria Labs and Austria’s CromaPharma, have propelled its success.
The company is also venturing into cutting-edge peptide-based treatments for obesity and diabetes, expecting to hit the market in multiple regions soon.
As Galenika celebrates its 80th anniversary, the company is poised for further expansion, targeting Latin America, the EU, and MENA markets, while staying committed to innovation and sustainability.
